Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Accumulated Expenses (2016 - 2025)

Moleculin Biotech (MBRX) has 9 years of Accumulated Expenses data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 55.57% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 55.57%, while the annual FY2024 figure was $3.3 million, 22.89% down from the prior year.
  • Accumulated Expenses reached $1.4 million in Q3 2025 per MBRX's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.3 million in Q4 2023 and bottomed at $106000.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $2.0 million, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: tumbled 94.18% in 2021, then soared 1322.64% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $606000.0 in 2021, then surged by 349.5% to $2.7 million in 2022, then skyrocketed by 58.48% to $4.3 million in 2023, then decreased by 22.89% to $3.3 million in 2024, then plummeted by 59.39% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $1.4 million in Q3 2025, $1.7 million in Q2 2025, and $2.0 million in Q1 2025.